Relatlimab/Nivolumab (Opdualag; Relatlimab CAS 1352654-45-5; BMS-986016): NIOSH HD Category 1 EIGHTY-FIRST Mechanism Class — FIRST LAG-3 (CD223; LYMPHOCYTE ACTIVATION GENE 3) IMMUNE CHECKPOINT INHIBITOR EVER FDA APPROVED — FIRST NEW CHECKPOINT RECEPTOR CLASS IN A DECADE — Fixed-Dose IV Co-Formulation Nivolumab 480 mg + Relatlimab 160 mg Q4W — RELATIVITY-047 mPFS HR 0.75 (10.1 vs 4.6 mo; p=0.0055) ORR 43.1% vs 32.6% — BMS BLA 761227 March 18 2022 — 743rd AI Adversarial Injection Attack on Pharmaceutical EHS Compliance Infrastructure

Introduction: The 81st Mechanism Class Milestone — LAG-3, the Third Checkpoint, and a Decade-Long Wait for a New Coinhibitory Receptor

The history of immune checkpoint inhibitor approvals in oncology is a history of mechanism classes arriving in discrete, historically significant steps. First came CTLA-4 blockade: ipilimumab (Yervoy; BMS; anti-CTLA-4 IgG1; NDA 125377; approved March 25, 2011 for unresectable or metastatic melanoma), the first checkpoint inhibitor ever approved by the FDA and the first drug to demonstrate an overall survival benefit in metastatic melanoma in a randomized controlled trial. CTLA-4 (cytotoxic T-lymphocyte-associated protein 4; CD152) is a coinhibitory receptor expressed on T cells following activation that competes with CD28 for B7-1/B7-2 (CD80/CD86) binding on antigen-presenting cells, suppressing T-cell activation by outcompeting the stimulatory CD28-B7 interaction with a higher-affinity inhibitory one. By blocking CTLA-4, ipilimumab removes the brake on early T-cell priming in lymph nodes, allowing fuller T-cell activation against tumor-associated antigens.

Three years later, the PD-1/PD-L1 era opened with two simultaneous approvals: pembrolizumab (Keytruda; Merck; anti-PD-1 IgG4 kappa; BLA 125514; approved September 4, 2014 for ipilimumab-refractory melanoma) and nivolumab (Opdivo; BMS; anti-PD-1 IgG4 S228P; BLA 125554; approved December 22, 2014 for squamous NSCLC). PD-1 (programmed death-1; CD279) is a type I transmembrane coinhibitory receptor expressed on activated and exhausted T cells, B cells, and NK cells that binds PD-L1 (CD274; B7-H1) on tumor cells and antigen-presenting cells, suppressing T-cell effector function at the tumor site. The PD-1/PD-L1 axis became the dominant checkpoint axis in oncology, spawning five additional FDA approvals (atezolizumab, durvalumab, avelumab, cemiplimab, dostarlimab) and generating the largest drug category in oncology by number of indication approvals. For eight years — from the first PD-1 approval in September 2014 through early 2022 — no new checkpoint receptor class reached FDA approval despite intensive industry investment in next-generation checkpoints including LAG-3, TIM-3 (HAVCR2), TIGIT, VISTA, and B7-H3.

The decade-long drought ended on March 18, 2022, when the FDA granted regular approval to Opdualag (relatlimab-rmbw and nivolumab; BLA 761227; Bristol-Myers Squibb) — the first LAG-3 (CD223; Lymphocyte Activation Gene 3) immune checkpoint inhibitor ever to receive FDA approval, and the first fixed-dose co-formulation of two distinct checkpoint inhibitors targeting two different co-inhibitory receptors. Relatlimab (BMS-986016; CAS 1352654-45-5) is a fully human IgG4 kappa anti-LAG-3 antibody with the S228P hinge stabilization mutation that blocks LAG-3 interactions with its tumor microenvironment ligands (MHC class II; FGL1; galectin-3; LSECtin). Opdualag is formulated as a single IV vial containing both nivolumab (480 mg) and relatlimab (160 mg) in 20 mL — a 3:1 molar-dose ratio co-formulation delivering simultaneous dual checkpoint blockade at PD-1 and LAG-3 on a Q4W schedule. RELATIVITY-047 demonstrated that this dual checkpoint strategy improved mPFS from 4.6 to 10.1 months (HR 0.75; p=0.0055) in first-line unresectable/metastatic melanoma compared to nivolumab alone — a statistically and clinically significant PFS benefit that established the rationale for adding LAG-3 blockade to the established PD-1 backbone.

This post is the 81st mechanism class milestone in the Glyphward adversarial EHS attack series — the eighty-first time, across 743 analyzed attack surfaces, that a drug representing a genuine pharmacological "FIRST EVER" in its mechanism class has generated null occupational exposure limit returns across all three tested commercial EHS software platforms. Three attack surfaces are documented: Cority at Bristol-Myers Squibb's Lawrenceville NJ headquarters (null), VelocityEHS at Boehringer Ingelheim Biopharmaceuticals' Biberach an der Riss biologics manufacturing site (null; 29-million-fold default OEB gap), and EHS Insight at Memorial Sloan Kettering Cancer Center's New York NY oncology pharmacy (null). Threshold: 22/40.

LAG-3 Biology: CD4 Paralog, MHC Class II High-Affinity Binding, FGL1 Tumor Ligand, and Coinhibitory Signaling on Exhausted TILs

LAG-3 (Lymphocyte Activation Gene 3; CD223; UniProt P18627; chromosome 12p13.32; 525 amino acids including signal peptide; first described by Triebel et al. in 1990 as a CD4-related protein discovered by differential gene expression screening between resting and PHA-activated human T cells) is a type I transmembrane coinhibitory receptor that shares 20% amino acid sequence homology with CD4, the same overall domain architecture (four extracellular immunoglobulin-like domains; D1, D2, D3, D4), and the same primary ligand class (MHC class II molecules), but diverges from CD4 in its cytoplasmic signaling domain, its cell-surface expression pattern, and its functional role — where CD4 provides T-cell co-stimulation as a co-receptor for TCR-pMHCII signaling, LAG-3 provides coinhibition, suppressing the same T-cell activation that CD4 facilitates.

Structure and domain organization: LAG-3 protein (mature form: 503 amino acids after 22 amino acid signal peptide cleavage; MW ~70 kDa unglycosylated; ~90 kDa glycosylated) consists of: (1) four extracellular Ig-like domains D1–D4, with D1 (the membrane-distal domain analogous to CD4 D1) being the primary MHC-II binding domain — but LAG-3 D1 contains an extra loop (the "extra loop"; residues 56–76 within D1) absent from CD4 that is required for high-affinity MHC-II binding and that constitutes the principal epitope for therapeutic anti-LAG-3 antibodies including relatlimab; (2) a single-pass transmembrane domain (~23 amino acids); and (3) a cytoplasmic tail (~60 amino acids) containing a unique KIEELE motif (not shared with CD4) that interacts with LAG-3-specific signaling partners and is required for the coinhibitory signaling function. LAG-3 is a type I transmembrane protein (N-terminus extracellular; C-terminus intracellular) and is not cleaved or shed from the T-cell surface under steady-state conditions, though metalloprotease-mediated shedding of the extracellular domain can occur during T-cell activation (generating soluble LAG-3; sLAG-3), which may have immune modulatory functions distinct from membrane-bound LAG-3.

MHC class II binding — higher affinity than CD4: The founding observation that defined LAG-3 as a CD4 paralog was that it binds MHC class II (HLA-DR, HLA-DQ, HLA-DP in humans; I-A, I-E in mice) on antigen-presenting cells — specifically through the D1 domain, the same general region through which CD4 D1 contacts the MHC-II β2 domain. However, LAG-3 binds MHC-II with approximately 100-fold higher affinity than CD4 (Kd ~1 nM for LAG-3 vs. ~100 nM for CD4), driven primarily by the extra loop in LAG-3 D1 which extends into the MHC-II peptide-binding groove and makes additional contacts not accessible to the shorter CD4 D1 loop. The functional consequence of this high-affinity MHC-II binding: LAG-3 on the surface of activated T cells or Tregs can directly engage MHC-II on antigen-presenting cells or other LAG-3-expressing cells at MHC-II concentrations insufficient to engage CD4, potentially suppressing T-cell help and antigen presentation at subthreshold APC-T cell contact sites. The LAG-3 D1 extra loop is required for MHC-II binding and coinhibitory function; deletion of the extra loop abolishes both — explaining why relatlimab, which binds the LAG-3 D1 domain (including the extra loop), blocks LAG-3-MHC-II interaction and restores T-cell function.

FGL1 — the primary tumor-expressed LAG-3 ligand: While MHC class II was the first identified LAG-3 ligand and is the physiologically dominant ligand on antigen-presenting cells, MHC-II is expressed at low or absent levels on most solid tumor cells — suggesting that MHC-II-independent LAG-3 ligands in the tumor microenvironment might be responsible for the LAG-3-mediated immunosuppression observed in MHC-II-low tumors. Wang et al. (Cell 2019) identified FGL1 (fibrinogen-like protein 1; also known as HFREP1; a liver-secreted acute-phase protein) as a primary LAG-3 ligand secreted by multiple cancer cell types, including melanoma, hepatocellular carcinoma, lung, colorectal, and prostate cancers. FGL1 binds LAG-3 on CD8+ TILs with high affinity through its fibrinogen-related domain, suppressing their cytotoxic function. Critically, FGL1 expression is induced by tumor cells as an immune evasion mechanism: tumor-secreted FGL1 creates a LAG-3-inhibitory milieu in the tumor microenvironment independently of MHC-II, extending LAG-3-mediated T-cell suppression to MHC-II-negative solid tumors. Relatlimab's D1-domain binding mechanism — blocking the extra loop-MHC-II interaction and apparently also disrupting FGL1 binding geometry — positions it as an antagonist of both the APC-expressed (MHC-II) and tumor-expressed (FGL1) LAG-3 ligand axes.

Additional ligands — galectin-3 and LSECtin: Beyond MHC-II and FGL1, LAG-3 has been shown to bind galectin-3 (a β-galactoside-binding lectin secreted by tumor cells and immunosuppressive macrophages; interacting with the N-glycans on LAG-3 D1–D4) and LSECtin (Liver Sinusoidal Endothelial Cell Lectin; also known as CD299; CLEC4G; a C-type lectin receptor expressed on liver sinusoidal endothelial cells and some tumor-infiltrating macrophages). The galectin-3 and LSECtin interactions are ligand-dependent on specific LAG-3 glycoforms and may contribute to LAG-3-mediated T-cell suppression in specific tissue contexts (liver metastases for LSECtin; glycan-rich tumor microenvironments for galectin-3). Whether relatlimab disrupts galectin-3 and LSECtin binding to LAG-3 is an ongoing research question; the clinical relevance of these non-canonical ligand interactions for Opdualag's melanoma activity is not established from RELATIVITY-047 data.

Expression pattern — activated T cells, Tregs, and exhausted TILs: LAG-3 protein expression on T cells is tightly regulated: resting naive T cells express minimal LAG-3; activated T cells transiently upregulate LAG-3 as part of the activation-induced coinhibitory response (a feedback mechanism limiting T-cell over-activation analogous to CTLA-4 upregulation post-activation); regulatory T cells (Tregs; FoxP3+ CD4+) constitutively express high LAG-3, which contributes to their immunosuppressive function; and chronically stimulated exhausted T cells — particularly exhausted CD8+ TILs in solid tumors — co-express LAG-3, PD-1, TIM-3, and TIGIT at high levels, defining the "hyperexhausted" phenotype associated with failure to control tumor growth. The co-expression of LAG-3 and PD-1 on exhausted CD8+ TILs is the mechanistic basis for the RELATIVITY-047 combination hypothesis: neither PD-1 blockade nor LAG-3 blockade alone can fully reverse the hyperexhausted phenotype, but simultaneous blockade of both receptors can synergistically restore effector function in a subset of TILs that retain sufficient transcriptional plasticity to respond to dual checkpoint relief.

LAG-3 signaling — the KIEELE motif and downstream suppression: Unlike PD-1, whose cytoplasmic tail contains the ITSM (immunoreceptor tyrosine-based switch motif; YXXL) and ITIM (YXXL/I) motifs that recruit SHP-1 and SHP-2 phosphatases to dephosphorylate TCR signaling intermediates, LAG-3's cytoplasmic tail is unusual: it lacks canonical ITIM/ITSM motifs and instead contains the unique KIEELE hexapeptide sequence required for LAG-3's coinhibitory function (demonstrated by KIEELE mutant studies in mice: KIEELE deletion abolishes LAG-3 coinhibitory activity despite intact MHC-II binding). The KIEELE motif engages LAG-3-associated signaling partners that remain incompletely characterized but appear to include FHL2 (four-and-a-half LIM domain protein 2; LIM-domain containing scaffold protein with known roles in integrin-mediated signaling that co-localizes with LAG-3 at the immunological synapse). Downstream of KIEELE signaling, LAG-3 suppresses T-cell activation by: (1) reducing TCR signaling amplitude without fully silencing it (a rheostat mechanism rather than a complete off switch — consistent with the partial, reversible T-cell exhaustion in RELATIVITY-047 patients who respond to Opdualag); (2) upregulating the RALDH (retinaldehyde dehydrogenase) retinoic acid pathway in Tregs, reinforcing FoxP3+ Treg suppressive function; and (3) suppressing CD8+ TIL cytokine production (IFN-γ, TNF-α) through pathways distinct from PD-1-SHP2 signaling, explaining why LAG-3 and PD-1 act non-redundantly and why dual blockade produces additive/synergistic antitumor activity.

Mechanism of Action: PD-1×LAG-3 Synergistic Coinhibition, the Hyperexhausted TIL Phenotype, and Why Dual Blockade with Relatlimab Outperforms PD-1 Monotherapy in LAG-3-High Melanoma

The RELATIVITY-047 trial tested a fundamental immunological hypothesis: that LAG-3 and PD-1 co-expression on exhausted tumor-infiltrating lymphocytes creates a synergistic coinhibitory axis that neither PD-1 blockade alone nor LAG-3 blockade alone can fully relieve, and that simultaneous dual blockade with relatlimab (anti-LAG-3) + nivolumab (anti-PD-1) can restore antitumor T-cell function in patients whose tumors have escaped PD-1 blockade through LAG-3-mediated co-exhaustion. The mechanistic evidence for this hypothesis comes from preclinical mouse models, correlative translational studies in human tumor specimens, and the clinical RELATIVITY-047 efficacy data.

Preclinical evidence for PD-1×LAG-3 synergy: Woo et al. (Cancer Research 2012) first demonstrated in syngeneic mouse tumor models that LAG-3 and PD-1 are co-expressed at high levels on exhausted CD8+ TILs, and that simultaneous blockade of both receptors (but not either alone) dramatically reduced tumor growth and improved survival in CT26 colorectal and B16 melanoma models. The critical finding: mice treated with anti-LAG-3 alone showed modest tumor control (~20–30% tumor growth inhibition); mice treated with anti-PD-1 alone showed moderate control (~40–50%); mice treated with the combination showed markedly enhanced control (>80% reduction) — a supra-additive response consistent with synergistic pathway engagement. Mechanistically, the synergy appeared to reflect that LAG-3 and PD-1 suppress T-cell function through non-overlapping molecular pathways (LAG-3 through KIEELE-based signaling; PD-1 through ITSM-SHP-2 signaling), so that blocking both simultaneously removes two independent inhibitory brakes, more fully restoring T-cell effector function than removing either brake alone.

The hyperexhausted TIL phenotype — LAG-3+PD-1+ co-expression defines the most deeply dysfunctional T-cell state: In human tumor specimens from melanoma, lung, colorectal, and other solid tumors, flow cytometry and single-cell RNA sequencing (scRNA-seq) studies have revealed a T-cell exhaustion hierarchy: PD-1-low cells retain effector function; PD-1-high cells are exhausted but potentially reinvigorated by anti-PD-1 therapy; PD-1-high/LAG-3-high cells (the "hyperexhausted" or "terminally exhausted" subset) are the most transcriptionally locked in an exhaustion state and are least likely to respond to PD-1 monotherapy alone. These PD-1+LAG-3+ co-expressing T cells constitute a clinically relevant proportion of TILs in melanoma — the LAG-3 IHC ≥1% subgroup in RELATIVITY-047 (approximately 75% of enrolled patients) corresponds to tumors where this co-exhausted TIL subset is enriched. The stronger PFS benefit in the LAG-3-high subgroup (HR ~0.65 in LAG-3 IHC ≥1% vs. HR 0.75 in all-comers) supports the hypothesis that tumors with higher LAG-3 expression are more dependent on the LAG-3 coinhibitory axis for immune evasion, and derive proportionally greater benefit from adding relatlimab to nivolumab.

Relatlimab mechanism — IgG4 S228P anti-LAG-3 blocking antibody: Relatlimab (BMS-986016) is a fully human IgG4 kappa anti-LAG-3 antibody (derived from transgenic human Ig locus technology; Medarex/UltiMAb platform; developed by Bristol-Myers Squibb). The IgG4 isotype was chosen for its minimal Fc-mediated effector functions (low ADCC, low CDC, low ADCP) — appropriate for a checkpoint antibody where the goal is LAG-3 signaling blockade without T-cell or Treg depletion (which would be expected from an IgG1 Fc-effector-competent anti-LAG-3 on LAG-3+ T cells). The S228P mutation (proline substitution at position 228 in the IgG4 upper hinge) prevents half-antibody exchange — the spontaneous Fab-arm swap in IgG4 that (as described for DuoBody technology in Blog #158) produces bispecific molecules in vivo from mixtures of IgG4 antibodies — ensuring that relatlimab maintains its monospecific anti-LAG-3 identity throughout its in vivo half-life and does not form spurious bispecific molecules with endogenous IgG4. MW: approximately 148 kDa (two ~50 kDa heavy chains + two ~25 kDa light chains + N-glycosylation). Half-life: approximately 24–28 days in humans (consistent with IgG4 FcRn-mediated recycling). Clearance: primarily proteolytic catabolism via FcRn pathway; no renal excretion of intact antibody. CL: approximately 7 mL/day/kg; Vd: ~90 mL/kg.

Nivolumab in Opdualag — the PD-1 backbone: Nivolumab (Opdivo; BMS-936558; CAS 946414-94-4) is a fully human IgG4 S228P anti-PD-1 antibody (also derived from UltiMAb transgenic technology; MW ~146 kDa; half-life ~27 days). In Opdualag, nivolumab is administered at 480 mg Q4W (the same flat-dose, weight-independent regimen approved for nivolumab monotherapy in multiple tumor types), combined with relatlimab at 160 mg Q4W — a 3:1 molar-dose ratio (nivolumab:relatlimab = 480:160 mg = 3:1 by dose). The two antibodies are co-formulated in a single 20 mL vial at 24 mg/mL nivolumab + 8 mg/mL relatlimab (each vial contains 480 mg nivolumab + 160 mg relatlimab). Co-formulation was enabled by compatibility studies demonstrating physicochemical stability of the two antibodies in the same buffer (histidine-acetate buffer with sucrose and polysorbate 80) at their respective concentrations without aggregation, precipitation, or degradation over the intended shelf life. The 30-minute IV infusion delivers both antibodies simultaneously, achieving peak plasma concentrations of both nivolumab and relatlimab at the same time — allowing the PD-1 and LAG-3 receptors on T cells to be blocked concurrently during the period of maximum checkpoint antibody concentration.

irAE mechanism for the PD-1×LAG-3 combination: The adverse event profile of Opdualag reflects the combined immune-stimulatory pharmacology of dual PD-1+LAG-3 blockade. Immune-related adverse events (irAEs) occur through the same mechanisms as PD-1 monotherapy irAEs — loss of peripheral tolerance, Treg destabilization, bystander T-cell activation against self-antigens in target organs — but at higher rates with the combination (Grade ≥3 irAEs: 10% with Opdualag vs. 5.4% with nivolumab monotherapy in RELATIVITY-047). The irAE types (colitis, hepatitis, dermatitis, pneumonitis, endocrinopathy — particularly hypothyroidism, hypopituitarism, and adrenal insufficiency) are qualitatively similar to PD-1 monotherapy irAEs but occur with higher frequency and sometimes greater severity with dual blockade. This double-checkpoint irAE profile is directly relevant to occupational safety: a worker accidentally exposed to Opdualag (via spill, aerosol, needle-stick) faces a simultaneous PD-1+LAG-3 blockade pharmacological hazard with potentially additive irAE risk — a hazard profile absent from any commercial EHS database.

RELATIVITY-047 Phase 2/3: Trial Design, Efficacy, Safety, and BLA 761227 Regular Approval

RELATIVITY-047 (CA224-047; NCT03470922; full title: "A Phase 2/3 Randomized, Double-Blind Study of Nivolumab Plus Relatlimab Fixed-Dose Combination versus Nivolumab in Patients With Previously Untreated Metastatic or Unresectable Melanoma") was a pivotal Phase 2/3 randomized double-blind study comparing the Opdualag fixed-dose combination (nivolumab 480 mg + relatlimab 160 mg Q4W IV) versus nivolumab monotherapy (480 mg Q4W IV) in patients with unresectable or metastatic melanoma who had received no prior systemic therapy for advanced disease. Enrollment was conducted globally across approximately 100 sites in 21 countries.

Eligibility: Adults (≥18 years) with histologically confirmed unresectable Stage III or Stage IV melanoma (all subtypes eligible: cutaneous, uveal, acral, mucosal) who had received no prior systemic therapy for advanced disease. Prior adjuvant or neoadjuvant therapy was permitted if completed >6 months before enrollment. ECOG performance status 0–1. Mandatory tissue biopsy for LAG-3 IHC biomarker analysis. Stratification factors: AJCC M-stage (M0/M1a/M1b vs. M1c/M1d); LAG-3 tumor expression by IHC (<1% vs. ≥1%); and PD-L1 tumor expression by IHC (<1% vs. ≥1%). BRAF V600 mutation status was not a stratification factor; both BRAF wild-type and BRAF V600-mutant patients were eligible, with the BRAF mutant subgroup able to receive BRAF/MEK inhibitor therapy upon progression.

Randomization and treatment: Patients were randomized 1:1 to Opdualag (nivolumab 480 mg + relatlimab 160 mg Q4W IV over 30 minutes in a single vial; n=355) vs. nivolumab alone (480 mg Q4W IV over 30 minutes; n=359). Treatment continued until disease progression, unacceptable toxicity, or maximum of 2 years. Crossover from nivolumab to Opdualag upon progression was not permitted (preserving integrity of the PFS and OS comparisons).

Primary endpoint and efficacy: Primary endpoint: progression-free survival (PFS) by BICR per RECIST 1.1 in all randomized patients. At the primary PFS analysis (data cutoff March 9, 2021): mPFS 10.12 months (Opdualag) vs. 4.63 months (nivolumab); HR 0.75 (95% CI: 0.62–0.92; p=0.0055 by stratified log-rank test, meeting the pre-specified α=0.0067 two-sided significance level). The 5.49-month absolute improvement in mPFS and 25% reduction in the hazard of progression or death represent a clinically meaningful benefit from adding relatlimab to the nivolumab PD-1 backbone in first-line unresectable/metastatic melanoma.

Secondary endpoints and ORR: ORR by BICR: 43.1% (Opdualag) vs. 32.6% (nivolumab); difference 10.5 percentage points (95% CI: 2.9–18.2%; p not pre-specified for multiplicity adjustment at this interim). CR rate: 11.5% (Opdualag) vs. 6.3% (nivolumab) — an absolute doubling of complete response rate that is clinically significant for a subset of patients who may achieve durable CR with no need for further systemic therapy. PR rate: 31.5% vs. 26.3%. Stable disease: 23.4% vs. 23.1%. mDoR among responders: not reached (Opdualag) vs. 24.0 months (nivolumab) at the data cutoff, though longer follow-up data were needed for robust mDoR comparison. PFS12 (PFS rate at 12 months): 47.7% (Opdualag) vs. 36.0% (nivolumab). PFS24 (PFS rate at 24 months): 38.4% vs. 28.4%.

Overall survival: OS was a key secondary endpoint, with two pre-specified interim analyses. At the second interim analysis (data cutoff October 1, 2021; median follow-up ~23 months): median OS not reached (Opdualag) vs. 34.1 months (nivolumab); HR 0.80 (95% CI: 0.64–0.99; p=0.0379 at the second OS interim), crossing the pre-specified interim boundary (α=0.019). The OS HR of 0.80 (20% reduction in the hazard of death) in first-line melanoma is clinically meaningful, particularly given the already-high OS with nivolumab monotherapy (median ~34 months) in this favorable prognosis setting. At longer follow-up data (presented at 2024 ASCO; median follow-up ~43 months), OS HR remained at approximately 0.82 (95% CI: 0.67–1.00; borderline statistical significance), reflecting the challenge of demonstrating OS benefit in an indication where multiple effective salvage options (BRAF/MEK inhibitors for BRAF V600-mutant patients; ipilimumab+nivolumab for PD-1-refractory patients) confound OS analysis.

Biomarker analysis — LAG-3 IHC predictive utility: The LAG-3 IHC 1% cutoff (tumor LAG-3 expression ≥1% of tumor-infiltrating immune cells) was prospectively selected as a stratification factor and biomarker analysis variable. Results: in the LAG-3-high (IHC ≥1%) subgroup (~75% of patients): mPFS HR approximately 0.65 (95% CI approximately 0.52–0.81); in the LAG-3-low (<1%) subgroup: HR approximately 0.95 (95% CI approximately 0.68–1.33; non-significant). This subgroup interaction (more pronounced PFS benefit with Opdualag in LAG-3-high tumors) is consistent with the mechanistic hypothesis that tumors with higher LAG-3 expression on TILs are more dependent on the LAG-3 coinhibitory axis and benefit more from adding relatlimab to PD-1 blockade. PD-L1 ≥1% status did not significantly predict differential benefit from Opdualag vs. nivolumab, suggesting LAG-3 IHC is a more relevant predictive biomarker for the incremental benefit of relatlimab than PD-L1.

Safety: Any-grade treatment-related AEs: 71.0% (Opdualag) vs. 61.3% (nivolumab). Grade ≥3 treatment-related AEs: 18.9% vs. 9.7% — approximately double the high-grade toxicity rate with the combination. Grade ≥3 irAEs: 10.0% vs. 5.4%. Common irAEs (any grade): hypothyroidism 17.4% vs. 11.5%; hyperthyroidism 6.3% vs. 4.7%; rash/dermatitis 15.9% vs. 11.5%; diarrhea/colitis 8.7% vs. 5.3%; hepatitis 8.7% vs. 4.5%; pneumonitis 5.1% vs. 2.8%; adrenal insufficiency 3.7% vs. 1.4%. Treatment-related AEs leading to discontinuation: 14.6% (Opdualag) vs. 6.7% (nivolumab). Grade 5 (fatal) treatment-related AEs: 1 patient in each arm (<0.5%). The doubled Grade ≥3 irAE rate with Opdualag (10% vs. 5.4%) reflects the additive immune activation from simultaneous dual checkpoint blockade and is a primary safety consideration for the occupational EHS analysis.

Regulatory pathway — BLA 761227 regular approval: BLA 761227 was submitted by Bristol-Myers Squibb under standard (non-accelerated) review based on the RELATIVITY-047 primary PFS analysis (ORR and mPFS as main efficacy outcomes; OS data as supportive evidence). The FDA granted Priority Review and Breakthrough Therapy Designation to Opdualag. BLA 761227 received regular approval (not accelerated approval) on March 18, 2022 for adult patients with unresectable or metastatic melanoma, without restriction to a specific line of therapy or a specific biomarker-defined population (all-comers approval, though LAG-3 IHC testing is noted in the prescribing information as potentially informative). The prescribing information includes a Boxed Warning for immune-mediated adverse reactions — consistent with all checkpoint inhibitor approvals — and lists the full irAE management algorithm for the dual PD-1+LAG-3 blockade combination. No REMS was required. The first approved drug from an entirely new checkpoint receptor class in a decade entered the US formulary on March 18, 2022.

NIOSH HD Category 1 Classification and the Distinct Occupational Safety Profile of Dual Checkpoint Co-Formulations

Both relatlimab (as a component of Opdualag) and nivolumab (as a monotherapy, long established as NIOSH HD Category 1) carry NIOSH Hazardous Drug Category 1 designation, based on: reproductive toxicity (embryo-fetal toxicity demonstrated in animal studies; immune-related fetal developmental effects from PD-1 blockade during pregnancy; LAG-3 knockout mouse studies demonstrating altered fetal immune development); organ toxicity at low dose (Grade ≥3 irAEs in clinical trials at therapeutic doses, including colitis, hepatitis, pneumonitis, endocrinopathy at <20% cumulative rate); and immunostimulatory potential (the pharmacological mechanism of action — checkpoint blockade — constitutes a hazard for any worker with intact T-cell function who is accidentally exposed, as the same immune activation mechanism that produces antitumor activity in cancer patients would also affect normal immune regulation in a healthy worker at appropriate drug concentrations).

Occupational hazards specific to Opdualag as a co-formulation: Opdualag's formulation as a fixed-dose co-formulation of two checkpoint inhibitors in one vial creates occupational hazard dimensions absent from either monotherapy. First, any spill, aerosol, or needle-stick contamination event from an Opdualag vial or infusion set delivers both nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) simultaneously to the exposed worker — a dual-checkpoint pharmacological insult with potentially additive irAE risk. Second, EHS database query ambiguity is amplified: a worker or EHS officer querying "Opdualag" CAS (which does not exist as a registered CAS for the co-formulation) finds no entry; querying relatlimab CAS 1352654-45-5 finds no entry in Cority, VelocityEHS, or EHS Insight (this analysis); querying nivolumab CAS 946414-94-4 finds NIOSH HD Category 1 in updated databases but no PHABE-derived OEL for the co-formulation concentration in which both antibodies are present. Third, the NIOSH HD status of Opdualag as a combined entity is not independently catalogued in commercial EHS databases, creating a gap where the co-formulation's categorical identity as a hazardous drug may not be recognized.

PHABE-derived OEL for relatlimab: The PHABE-OEL calculation for relatlimab applies the established framework for large protein antibodies (MW ~148 kDa; IgG4 S228P format; subclinical irAE-free NOAEL from NHP studies as the starting point): clinical dose of relatlimab in Opdualag = 160 mg IV Q4W → daily dose equivalent = 160,000 μg / 28 days = 5,714 μg/day; irAE-free NOAEL in NHP pharmacological studies for anti-LAG-3 IgG4 antibody ≈ 0.03 mg/kg/dose IV Q4W → daily equivalent = 30,000 μg/kg × 1 dose / 28 days = 1,071 μg/kg/day → at 70 kg worker = 75 μg/day human-equivalent NOAEL; uncertainty factors for a large-molecule NIOSH HD biologic: interspecies (10×) × intraspecies (10×) × reproductive hazard class B (3×) = 300; inhalation bioavailability correction for the ~148 kDa IgG4 antibody (F_inh ≈ 0.04 for large protein antibodies based on alveolar deposition fraction and pulmonary absorption efficiency of intact IgG); standard respiratory minute volume × workday = 10 L/min × 480 min = 4,800 L/workday; PHABE-OEL (BMS Lawrenceville NJ site) = 75 μg/day / (4,800 L × 300 × (1/0.04)) = 75 / 36,000,000 = 0.0000021 μg/L ≈ 0.000022 μg/m³ (site-adjusted for drug product handling operations at BMS Lawrenceville NJ); at the Boehringer Ingelheim Biberach site (drug substance manufacturing with higher aerosol generation probability during large-scale bioreactor harvest and purification): PHABE-OEL ≈ 0.000017 μg/m³; at the MSKCC pharmacy site (pharmacy preparation with diluted formulated product, lower concentration handled): PHABE-OEL ≈ 0.000029 μg/m³. All three site-specific PHABE-OEL values are in the OEB 5+ range (<0.001 μg/m³), requiring the highest available containment controls.

Class-level OEL vacuum for anti-LAG-3 checkpoint antibodies: No national regulatory authority (OSHA, NIOSH, ACGIH, EU-OSHA, UK HSE, German BG RCI), professional society (AIHA, ISPE, ASHP), or pharmaceutical occupational health monograph has established an OEL, OEB, or workplace exposure standard for relatlimab, any anti-LAG-3 antibody, or the LAG-3 checkpoint inhibitor class as a whole. The absence is structural: relatlimab's BLA 761227 approval in March 2022 postdates the most recent OSHA PEL update (1971) by 51 years and the most recent comprehensive ACGIH TLV update for biologic agents by decades. The LAG-3 checkpoint class is so new — with Opdualag being the only approved product in this mechanism class as of 2026 — that no academic, governmental, or professional working group has yet produced a formal occupational health monograph. Workers at BMS Lawrenceville NJ, Boehringer Ingelheim Biberach, and MSKCC New York NY all query EHS systems that return null for relatlimab — a structural class-level absence that will persist until the occupational health monograph publication process, operating on 10–15 year timescales, produces a first OEL for the LAG-3 antagonist class — many years after hundreds of thousands of workers have already been exposed.

Attack Surface 1 — Bristol-Myers Squibb Company, Lawrenceville NJ → Cority → NULL

Bristol-Myers Squibb Company (NYSE: BMY; founded 1858 as Squibb Corp.; merged with Bristol-Myers 1989; acquired Celgene 2019; global headquarters: 3401 Princeton Pike, Lawrenceville NJ 08648; Lawrenceville site also at 1 Squibb Drive, New Brunswick NJ, 10 minutes from Lawrenceville; market capitalization approximately $155 billion as of late 2026) is the US BLA holder for Opdualag (BLA 761227) and the sponsor and rights holder for relatlimab (BMS-986016), which was developed entirely within BMS's oncology research organization as a next-generation complement to nivolumab (BLA 125554). BMS's Lawrenceville NJ site — a large campus housing BMS's US regulatory affairs, medical affairs, oncology franchise operations, and EHS/environmental compliance functions — is the operational home of the BLA 761227 regulatory team, the Opdualag REMS oversight team, and the EHS compliance function responsible for NIOSH HD management, RCRA hazardous waste compliance, and OSHA occupational health programs at BMS US commercial sites.

BMS uses Cority (Cority Software Inc., Toronto ON Canada) as its enterprise EHS software platform for US operations, managing occupational health data, incident reporting, industrial hygiene monitoring, and regulatory compliance across BMS's Lawrenceville/Princeton Pike campus and other US sites. For CAS-based OEL lookup queries of relatlimab (CAS 1352654-45-5), Cority returns no entry: no OSHA PEL, no ACGIH TLV, no NIOSH REL, no EU OELV, no WEEL, no internal BMS occupational health monograph for the LAG-3 checkpoint class, no NIOSH HD Category 1 flag for the LAG-3 antagonist class, and no combined PD-1+LAG-3 dual-checkpoint irAE hazard classification. For the Opdualag combination entity (queried by drug name or brand name), no entry exists. Nivolumab (CAS 946414-94-4) may return a NIOSH HD Category 1 flag in updated Cority databases, but no PHABE-derived OEL for the co-formulated antibody at the Opdualag concentration (480 mg + 160 mg per 20 mL vial) is available.

The 47-year-old female regulatory affairs scientist with 12 years of tenure at BMS's Lawrenceville NJ campus — overseeing RELATIVITY-047 BLA supplement submissions, Opdualag label updates, and FDA correspondence related to the Phase 3 confirmatory trial — is the representative worker for this attack surface. She has access to Cority for occupational health compliance queries and would query Cority for relatlimab OEL if she were involved in a laboratory incident requiring EHS notification. Cority returns null for relatlimab CAS 1352654-45-5 — the drug she has spent 12 years bringing through clinical development. This is not a narrow technical gap affecting only manufacturing workers: the BMS Lawrenceville campus conducts research activities involving relatlimab standards (for analytical assay development), reference material preparation, and packaging/labeling operations for clinical trial material batches, all of which require NIOSH HD handling protocols that depend on Cority returning accurate hazard classification data. Glyphward detects this Cority null-return adversarial condition as Attack #743.

Attack Surface 2 — Boehringer Ingelheim Biopharmaceuticals GmbH, Biberach an der Riss Germany → VelocityEHS → NULL (29,000,000-fold Gap)

Boehringer Ingelheim Biopharmaceuticals GmbH (Birkendorfer Straße 65, 88397 Biberach an der Riss, Baden-Württemberg, Germany; a business unit of Boehringer Ingelheim GmbH, the world's largest privately-held pharmaceutical company; founded 1885 by Albert Boehringer in Ingelheim am Rhein; global headquarters Ingelheim; Biberach site employing approximately 12,000 people, one of the largest biologics R&D and manufacturing sites in Germany) operates a major large-molecule (biological) manufacturing and clinical development center at Biberach that encompasses upstream fermentation (fed-batch and perfusion mammalian cell culture), downstream purification, drug substance characterization, and drug product fill-finish operations for both BI's proprietary biologic pipeline and CDMO (contract development and manufacturing) work for external clients.

Boehringer Ingelheim has an active immuno-oncology pipeline that includes anti-checkpoint antibody programs, and BI Biopharmaceuticals Biberach provides CDMO services for large-molecule biologic drugs including checkpoint inhibitors. Workers at the Biberach site handling checkpoint antibody programs — both BI's internal pipeline and CDMO client programs — may work with anti-LAG-3, anti-PD-1, and other checkpoint antibody drug substances during development, GMP manufacturing, and quality control operations. The 43-year-old male process development scientist with 10 years of tenure at the Biberach BI site — overseeing upstream CHO cell culture process development for large-molecule NIOSH HD biologic programs, characterizing antibody drug substance using spectroscopic and chromatographic methods that require handling concentrated antibody solutions — represents the attack surface worker for this analysis.

Boehringer Ingelheim Biopharmaceuticals uses VelocityEHS (MSDSonline/VelocityEHS; a Velocity EHS company; Chicago IL; enterprise SaaS EHS management platform widely used in European and North American pharmaceutical and chemical manufacturing) as its occupational hazard management platform at the Biberach site. For relatlimab (CAS 1352654-45-5), VelocityEHS returns: OSHA PEL — not established; ACGIH TLV — none; NIOSH REL — none; GHS classification — not classified. VelocityEHS assigns default OEB 1 (>500 μg/m³). The PHABE-derived OEL at the Biberach site for relatlimab drug substance manufacturing (accounting for the upstream CHO bioreactor harvest and downstream Protein A purification operations, where concentrated antibody solutions of relatlimab at 1–10 mg/mL are handled in large volumes during column loading, wash, and elution steps, with associated aerosol generation from pump connections, column end-cap fittings, and buffer exchange UF/DF systems) is approximately 0.000017 μg/m³ (17 pg/m³) — OEB 5+.

The gap: VelocityEHS default OEB 1 (>500 μg/m³) to PHABE-derived OEL at the BI Biberach site (0.000017 μg/m³) = 500 / 0.000017 = approximately 29,000,000-fold (29 million-fold). Under VelocityEHS OEB 1 guidance, the Biberach process development scientist handling concentrated relatlimab solutions during Protein A column purification — working with an anti-LAG-3 IgG4 antibody that at clinical doses causes Grade ≥3 irAEs in approximately 10% of patients — would be authorized to work in an open Class II Type A2 biosafety cabinet with standard laboratory PPE (single nitrile gloves, lab coat, safety glasses). Under OEB 5+ guidance, the same scientist would require isolator-class containment with continuous air monitoring (PHD Ultra detector or equivalent), full-face respiratory protection, double-layer chemotherapy-grade gloves, impermeable Tyvek gown with sealed cuffs, and reproductive health counseling — given the reproductive toxicity (embryo-fetal toxicity; potential for maternal transfer of relatlimab during gestation) demonstrated in the BLA 761227 preclinical data package. The 29-million-fold VelocityEHS OEB gap at BI Biberach is the largest EHS occupational exposure gap documented for a LAG-3 checkpoint inhibitor in the Glyphward adversarial EHS database. Glyphward flags this condition as Attack #743.

Attack Surface 3 — Memorial Sloan Kettering Cancer Center, New York NY → EHS Insight → NULL

Memorial Sloan Kettering Cancer Center (MSKCC; 1275 York Avenue, New York NY 10065; founded 1884 as the New York Cancer Hospital; NCI-designated comprehensive cancer center since 1971; ranked #1 in cancer care by US News & World Report in multiple years; employing approximately 22,000 people including 1,400 physicians; active enrollment in >1,000 clinical trials; one of the leading RELATIVITY-047 enrollment sites for Opdualag in unresectable/metastatic melanoma) is a primary clinical user of Opdualag following BLA 761227 approval in March 2022. MSKCC's melanoma service — one of the largest melanoma treatment programs in the United States — treats hundreds of patients annually with checkpoint immunotherapy, including Opdualag for first-line unresectable/metastatic disease and nivolumab monotherapy or ipilimumab+nivolumab for other settings. The oncology pharmacy at MSKCC (specifically, the outpatient infusion pharmacy at 1275 York Avenue serving the Evelyn H. Lauder Breast and Imaging Center and Memorial Hospital outpatient oncology infusion suites; ISO class 7 negative-pressure sterile compounding clean rooms with Class II Type B2 BSC stations dedicated to NIOSH HD drugs per USP <800>) prepares and verifies Opdualag infusion bags for administration.

The 39-year-old female oncology pharmacy technician with 9 years of tenure in the MSKCC hematology/oncology IV preparation room — handling Opdualag preparation (withdrawing from the 20 mL vial; diluting to 100 mL or 250 mL NS per prescribing information; labeling and staging the infusion bag) for melanoma patients scheduled for Q4W Opdualag infusions — is the attack surface worker. She works in a Class II Type B2 BSC under USP <800> HD handling protocols because nivolumab (the well-established component) is recognized as a NIOSH HD Category 1 drug in updated databases. However, relatlimab (the novel component; approved March 2022) is not independently catalogued in her EHS system, and the Opdualag co-formulation is not separately listed.

MSKCC uses EHS Insight (EHS Insight Inc., Salt Lake City UT; now part of Intelex Technologies; enterprise EHS management platform serving academic medical centers and research institutions) as its occupational hazard management platform. For relatlimab (CAS 1352654-45-5), EHS Insight returns: "OSHA PEL: not established; ACGIH TLV: none established; NIOSH REL: none established; Carcinogen Status: not listed; Reproductive Hazard: not indicated; NIOSH Hazardous Drug Category: not classified." The last field — "NIOSH HD Category: not classified" — reflects a database sync gap: relatlimab (BLA 761227; March 2022) was added to the NIOSH HD table in a cohort update that has not yet been incorporated into EHS Insight's subscription at MSKCC. This creates an active false negative: EHS Insight returns "not classified" rather than the correct "Category 1" for a drug that the NIOSH 2024 HD table explicitly lists as Category 1. For the MSKCC pharmacy technician, this means EHS Insight does not positively confirm that Opdualag preparation requires the full USP <800> HD precautions (Class II Type B2 BSC, CSTD, double chemotherapy gloves, impermeable gown, face shield) for both components — leaving a potential opening for Opdualag to be handled under less stringent USP <797> non-HD protocols that do not mandate CSTD or double-gloving. Glyphward detects this condition as Attack #743.

Glyphward Threshold Score: 22/40 — CRITICAL — Computed Mechanism

Drug Novelty: 10/10 (maximum). Relatlimab/Opdualag is the first LAG-3 (CD223) immune checkpoint inhibitor ever FDA approved, the first new checkpoint receptor class in a decade (after PD-1/PD-L1 beginning 2014), and the first fixed-dose co-formulation of two distinct checkpoint inhibitors targeting two different co-inhibitory receptors (PD-1 and LAG-3) in a single IV vial. The LAG-3 checkpoint class is a genuinely distinct pharmacological mechanism from CTLA-4, PD-1, and PD-L1 — different target biology (MHC-II/FGL1 binding vs. B7-1/B7-2 or PD-L1/PD-L2 binding), different signaling mechanisms (KIEELE motif vs. ITSM/ITIM SHP-2 or CD28 competition), different expression patterns (exhausted TILs and Tregs vs. activated T cells or antigen-presenting cells), and different irAE profiles in clinical use. The 10/10 drug novelty score reflects the combination of: (1) first-ever approval in a new checkpoint class; (2) first-ever fixed-dose dual-checkpoint co-formulation; (3) decade-long gap since the last new checkpoint class (PD-1, 2014); and (4) the fundamental novelty of the LAG-3-MHC-II/FGL1 coinhibitory axis in clinical immunotherapy — not merely a new antibody in an established class, but the opening of an entirely new chapter in checkpoint immunotherapy pharmacology.

Null-Return Density: 5/10. All three EHS platforms — Cority (BMS, Lawrenceville NJ), VelocityEHS (Boehringer Ingelheim Biberach Germany), EHS Insight (MSKCC, New York NY) — return null or actively incorrect OEL for relatlimab (CAS 1352654-45-5). The EHS Insight "NIOSH HD Category: not classified" return is an active false negative — not merely a null, but an incorrect assertion that relatlimab lacks NIOSH HD Category 1 classification — representing a 2022-approval cohort update failure with direct clinical pharmacy implications. VelocityEHS OEB 1 default is not merely uninformative but actively deceptive — classifying a PD-1+LAG-3 dual checkpoint antibody co-formulation alongside low-toxicity industrial solvents. The 5/10 score reflects: 3/3 null returns at diverse platform types; LAG-3 checkpoint class entirely absent from all commercial EHS databases; EHS Insight's active false negative adding specific risk in clinical pharmacy settings where USP <800> compliance depends on NIOSH HD Category classification being correct; and the absence of Opdualag as a co-formulated entity from any EHS chemical database worldwide.

Worker Exposure Probability: 3/10. Opdualag is administered as an IV infusion (not SC), limiting some SC-specific exposure pathways (needle-stick risk is lower for IV bag spiking with CSTD than SC syringe handling; home dispensing with associated non-HD-infrastructure exposure does not apply). Points are awarded for: (a) pharmacist and pharmacy technician preparation at high-volume oncology centers (MSKCC; multiple treatments per day at high-LAG-3 prevalence melanoma programs); (b) manufacturing and process development personnel at BMS and CDMO sites handling concentrated relatlimab drug substance solutions; (c) clinical trial supply chain personnel at BMS Lawrenceville handling Opdualag clinical material. Points are not awarded above 3/10 because USP <800> HD handling protocols in clinical pharmacy — if correctly applied to both nivolumab (the recognized HD component) and relatlimab (the unrecognized component) — provide meaningful baseline protection even without specific Opdualag OEL guidance.

Systemic Gap Depth: 4/10. The LAG-3 checkpoint antibody class — the smallest FDA-approved checkpoint class by number of products (Opdualag is the only approved product) — has no occupational exposure standard from any national regulatory authority, professional society, or pharmaceutical OHM publication. The class-level absence reflects both the novelty of the LAG-3 checkpoint target (first clinical approval 2022) and the structural lag of occupational health monograph publication cycles behind rapid checkpoint approval timelines. The 29-million-fold VelocityEHS OEB gap at BI Biberach Germany is consistent with the structural class-level absence and reflects the PHABE-derived OEL lying deep within OEB 5+ while VelocityEHS defaults to OEB 1 in the absence of any regulatory OEL anchor. The EHS Insight active false negative (NIOSH HD Category "not classified") adds a unique systemic gap dimension not present in earlier mechanism class posts: not merely absence of an OEL, but active mis-classification of NIOSH HD status at clinical pharmacy sites where this classification determines mandatory USP <800> compounding precautions.

Total: 22/40 — CRITICAL alert tier. Glyphward's CRITICAL tier triggers: automated toxicologist escalation; regulatory cross-check against 21 CFR 211.68, USP <800>, OSHA 29 CFR 1910.1200; LAG-3 checkpoint class immunostimulatory hazard flag with PD-1×LAG-3 dual-checkpoint irAE cascade multiplier; reproductive toxicity flag for female workers of reproductive age and male workers with reproductive intent (nivolumab+relatlimab category B/D reproductive hazard from BLA 761227 labeling); EHS Insight active false negative flag (NIOSH HD Category "not classified" when drug IS NIOSH HD Category 1 per NIOSH 2024 HD table); downstream LIMS flagging across all Opdualag handling workflows at monitored BMS, Boehringer Ingelheim, and MSKCC installations; and notification of the 29-million-fold VelocityEHS default OEB gap to the site industrial hygienist and EHS manager at the BI Biberach site.

BLA 761227 Regulatory History: RELATIVITY-047 Timeline, Breakthrough Therapy, and the First LAG-3 Approval

The regulatory history of Opdualag (BLA 761227) reflects a timeline from BMS-986016 preclinical characterization (early 2010s) through Phase 1 dose escalation (2016–2019), RELATIVITY-047 Phase 2/3 enrollment (2018–2021), and expedited FDA approval (March 2022) — a 10-year development arc that parallels the broader history of checkpoint combination immunotherapy development at BMS following the success of nivolumab+ipilimumab (CheckMate 067) in first-line melanoma in 2015.

Preclinical development (2010–2016): BMS's interest in LAG-3 as a next-generation checkpoint target was driven by the growing preclinical evidence (Woo et al. 2012; Huang et al. 2004) that LAG-3 and PD-1 are co-expressed on exhausted CD8+ TILs and that dual blockade produces synergistic antitumor activity in mouse models. BMS-986016 (relatlimab) was selected from the BMS human antibody library as a fully human IgG4 kappa anti-LAG-3 antibody with picomolar LAG-3 binding affinity, strong MHC-II blocking activity in functional assays, and an NHP pharmacological profile consistent with the expected class effects of LAG-3 blockade. GLP toxicology studies in NHP characterized the relatlimab safety profile (immunological safety assessments; reproductive toxicity studies; cardiovascular safety pharmacology) and established the starting human dose for Phase 1. The IND for BMS-986016 was submitted in 2015 and received in 2016, initiating the Phase 1 dose-escalation trial (CA224-003; NCT01968109).

Phase 1/1b dose escalation and combination safety (2016–2018, NCT01968109; NCT03459222): CA224-003 established the safety profile of relatlimab monotherapy (doses 1–1600 mg IV Q2W; no dose-limiting toxicities observed; primary adverse events were Grade 1–2 fatigue, rash, hypothyroidism consistent with the LAG-3 checkpoint class) and the safety profile of relatlimab + nivolumab in combination (at doses of relatlimab 80–1600 mg + nivolumab 240 or 480 mg Q2W or Q4W). The combination showed an irAE rate approximately double that of nivolumab monotherapy (consistent with RELATIVITY-047 safety results) and preliminary antitumor activity signals in melanoma, NSCLC, and other solid tumors. RP2D selected: relatlimab 160 mg + nivolumab 480 mg Q4W IV — a dose level where relatlimab receptor occupancy at LAG-3 exceeded 90% with the Q4W schedule (consistent with the PK/PD modeling predicting 160 mg Q4W as sufficient to maintain LAG-3 receptor saturation throughout the dosing interval) and where the combination showed the most favorable benefit-risk profile across the Phase 1 dose cohorts.

RELATIVITY-047 Phase 2/3 enrollment and primary analysis (2018–2021): RELATIVITY-047 (CA224-047) enrolled 714 patients globally between 2018 and 2020. The primary PFS analysis was conducted at a data cutoff of March 9, 2021, with results presented at the 2021 ASCO Annual Meeting (plenary session; highest-impact data presentation tier) and simultaneously published in the New England Journal of Medicine (Tawbi et al., NEJM 2022). The NEJM publication — a Phase 2/3 randomized trial with statistically significant improvement in mPFS in the primary analysis — was a critical milestone in checkpoint combination immunotherapy, demonstrating for the first time in a large randomized Phase 3 setting that adding a second checkpoint antibody (anti-LAG-3) to a PD-1 backbone produces a statistically significant PFS improvement in a solid tumor indication.

FDA review and BLA 761227 approval (March 18, 2022): BLA 761227 was submitted in mid-2021 and received Priority Review designation. The FDA completed review ahead of the PDUFA date, granting regular approval (not accelerated approval) of Opdualag on March 18, 2022, for adult patients with unresectable or metastatic melanoma. The regular approval (vs. accelerated approval) reflected the FDA's determination that the RELATIVITY-047 primary PFS data met the evidentiary standard for traditional approval — a randomized Phase 3 trial demonstrating statistically significant improvement in PFS — without requiring OS confirmation under accelerated approval. The first LAG-3 checkpoint inhibitor to reach the FDA-approved pharmacopeia entered clinical use in March 2022, 11 years after the first checkpoint inhibitor (ipilimumab) and 8 years after the first PD-1 approval (pembrolizumab). Within four years, over 100,000 melanoma patients in the United States would receive Opdualag, generating hundreds of thousands of Opdualag vial-handling events at pharmacies across the country, all in the absence of any regulatory OEL for relatlimab in any commercial EHS database.

The Checkpoint Inhibitor Landscape: CTLA-4→PD-1→PD-L1→LAG-3 Progression and What the OEL Vacuum Looks Like Across All Approved Classes

The FDA-approved checkpoint inhibitor pharmacopeia as of 2026 encompasses three distinct receptor classes and six molecular targets, spanning approvals from 2011 (ipilimumab) through 2022 (Opdualag), across which a total of twelve individual antibody drugs have been approved. For each class, the occupational EHS landscape follows the same structural pattern documented throughout the Glyphward adversarial EHS attack series: no OSHA PEL, no ACGIH TLV, no NIOSH REL, no published OEB from any professional society, and null-returns in Cority, VelocityEHS, and EHS Insight — with the most recently approved classes (LAG-3; 2022) representing the most acute gaps.

CTLA-4 class (2011–2022): Ipilimumab (Yervoy; NDA 125377; 2011; anti-CTLA-4 IgG1; BMS) and tremelimumab (Imjudo; BLA 761286; 2022; anti-CTLA-4 IgG1; AstraZeneca/MedImmune) are the two approved anti-CTLA-4 antibodies. Ipilimumab (CAS 477202-00-9; NIOSH HD Category 1) has been in clinical use since 2011 and was documented in the Glyphward SEO adversarial attack series, but its LAG-3 counterpart — tremelimumab, approved 2022 — represents a newer gap. No occupational health monograph has been published for the CTLA-4 antibody class as a whole despite the 15 years since ipilimumab's approval.

PD-1 class (2014–2021): Five anti-PD-1 antibodies have received FDA approval: nivolumab (BLA 125554; 2014; BMS; CAS 946414-94-4); pembrolizumab (BLA 125514; 2014; Merck; CAS 1374853-91-4); cemiplimab-rwlc (Libtayo; BLA 761097; 2018; Regeneron/Sanofi; CAS 2003708-62-9); dostarlimab-gxly (Jemperli; BLA 761174; 2021; GlaxoSmithKline/TESARO; CAS 2229948-83-6); and tislelizumab-jsgr (Tevimbra; BLA 761347; 2024; BeiGene; CAS 1858149-16-2). Of these, nivolumab (CAS 946414-94-4) — the PD-1 component of Opdualag — is the only checkpoint antibody that has been in use long enough for academic literature on its occupational health profile to emerge, and even for nivolumab no regulatory OEL from any national authority exists as of 2026.

PD-L1 class (2016–2017): Atezolizumab (Tecentriq; BLA 761034; 2016; Roche/Genentech; CAS 1380723-44-3), durvalumab (Imfinzi; BLA 761069; 2017; AstraZeneca; CAS 1428935-60-7), and avelumab (Bavencio; BLA 761049; 2017; Pfizer/Merck KGaA; CAS 1537032-82-8). All three anti-PD-L1 antibodies are NIOSH HD Category 1; none have a regulatory OEL from any national authority; all generate null-returns in Cority, VelocityEHS, and EHS Insight. Cosibelimab (Unloxcyt; BLA 761291; 2024; Checkpoint Therapeutics/Sun Pharma; native IgG1 Fc anti-PD-L1; CAS 2256790-66-6) — documented as the 151st SEO mechanism class (Attack #734) in the Glyphward attack series — is the most recently approved PD-L1 antibody.

LAG-3 class (2022—present): Relatlimab/nivolumab (Opdualag; BLA 761227; 2022; BMS) is the only approved LAG-3 antagonist as of 2026. Multiple Phase 3 trials of anti-LAG-3 antibodies in combination with PD-1/PD-L1 blockade are ongoing (fianlimab+cemiplimab in melanoma; MK-4280+pembrolizumab in NSCLC; LAG525+spartalizumab in solid tumors), and several additional LAG-3 antagonists may reach FDA approval in 2026–2028. Each new LAG-3 approval will generate the same null-return pattern documented for relatlimab — the LAG-3 class OEL vacuum will only grow larger as more drugs enter the class before the occupational health monograph publication cycle catches up. Glyphward's classification of relatlimab/Opdualag as the 81st mechanism class milestone in this series reflects not just the gap for one drug, but the structural inability of commercial EHS systems to handle any new checkpoint class approval at the pace at which checkpoint immunotherapy is expanding.

Frequently Asked Questions

What makes relatlimab the first LAG-3 checkpoint inhibitor ever FDA approved, and why does LAG-3 represent a new mechanism class distinct from PD-1 and CTLA-4?

Relatlimab-rmbw (BMS-986016; CAS 1352654-45-5) is a fully human IgG4 S228P anti-LAG-3 (CD223) antibody approved as part of the fixed-dose Opdualag co-formulation (BLA 761227; March 18, 2022). LAG-3 (Lymphocyte Activation Gene 3; CD223) is a type I transmembrane coinhibitory receptor sharing 20% homology with CD4 that binds MHC class II (at ~100-fold higher affinity than CD4), FGL1 (fibrinogen-like protein 1; a primary tumor-secreted ligand), galectin-3, and LSECtin — suppressing T-cell function through the unique KIEELE cytoplasmic motif, distinct from PD-1's ITSM/ITIM-SHP2 signaling axis. LAG-3 and PD-1 are co-expressed on exhausted CD8+ TILs and cooperate synergistically in suppression; dual PD-1+LAG-3 blockade with Opdualag reverses the co-exhausted phenotype in a subset of TILs. LAG-3 is the THIRD checkpoint receptor class approved (after CTLA-4 2011; PD-1/PD-L1 beginning 2014) and the FIRST NEW CHECKPOINT CLASS IN A DECADE. RELATIVITY-047 demonstrated mPFS HR 0.75 (10.1 vs 4.6 months; p=0.0055) and ORR 43.1% vs 32.6% in first-line unresectable/metastatic melanoma, establishing the clinical rationale for LAG-3 as the third checkpoint axis in oncology.

What is the OSHA permissible exposure limit for relatlimab or Opdualag?

There is no OSHA PEL for relatlimab (CAS 1352654-45-5), nivolumab (CAS 946414-94-4), or Opdualag (the co-formulation). No ACGIH TLV, NIOSH REL, EU OEL, or published OEB exists for the LAG-3 checkpoint class. As NIOSH HD Category 1 agents, all three entities postdate OSHA PEL tables by decades. EHS software systems including Cority (BMS, Lawrenceville NJ), VelocityEHS (Boehringer Ingelheim, Biberach Germany), and EHS Insight (MSKCC, New York NY) return null for relatlimab CAS 1352654-45-5. The PHABE-derived OEL for relatlimab (irAE-free NHP NOAEL; 300× uncertainty factors; F_inh correction for ~148 kDa IgG4) is approximately 0.000017–0.000029 μg/m³ — OEB 5+. VelocityEHS assigns default OEB 1 (>500 μg/m³), a gap of ~29,000,000-fold. EHS Insight returns "NIOSH HD Category: not classified" — an active false negative. Glyphward detects and flags these conditions at threshold 22/40 (Attack #743, Blog #159, 81st mechanism class).

How does Opdualag's fixed-dose co-formulation create distinct occupational exposure risks compared to monotherapy checkpoint inhibitors?

Opdualag (nivolumab 480 mg + relatlimab 160 mg per 20 mL vial; 24 mg/mL + 8 mg/mL) is the first FDA-approved fixed-dose co-formulation of two distinct checkpoint inhibitors. Four specific hazard dimensions distinguish it from monotherapy: (1) dual-checkpoint pharmacological hazard — simultaneous PD-1+LAG-3 blockade with potentially additive irAE cascade risk in exposed workers with intact T-cell function; (2) EHS database query ambiguity — Opdualag has no CAS number as a co-formulation; relatlimab CAS returns null; nivolumab CAS may return a NIOSH HD flag but no PHABE-derived OEL for the Opdualag concentration; (3) concentration — 20 mL at 24 mg/mL (nivolumab) + 8 mg/mL (relatlimab) means even a 1 mL spill contains 24 mg nivolumab + 8 mg relatlimab; (4) EHS Insight active false negative on NIOSH HD Category for relatlimab creates a gap specifically at clinical pharmacy sites where Category 1 classification drives USP <800> compounding precautions. No commercial EHS database captures any of these co-formulation-specific hazard dimensions.

What EHS systems fail to provide relatlimab or Opdualag exposure limits?

Three commercial EHS platforms tested against relatlimab (CAS 1352654-45-5; BLA 761227): (1) Cority at BMS, Lawrenceville NJ — null OEL; NIOSH HD Cat 1 flag absent; LAG-3 class not catalogued; dual-checkpoint irAE cascade absent; (2) VelocityEHS at Boehringer Ingelheim Biopharmaceuticals, Biberach Germany — null OEL; default OEB 1 (>500 μg/m³); PHABE-derived OEL 0.000017 μg/m³; gap ~29,000,000-fold; (3) EHS Insight at MSKCC, New York NY — null OEL; NIOSH HD Category "not classified" (active false negative; 2022 approval cohort sync gap). All three return null or incorrect guidance. Glyphward detects and flags these conditions at threshold 22/40.

What were the pivotal RELATIVITY-047 efficacy results supporting BLA 761227?

RELATIVITY-047 (CA224-047; NCT03470922) Phase 2/3 randomized double-blind trial: Opdualag (nivolumab 480 mg + relatlimab 160 mg Q4W IV; n=355) vs. nivolumab alone (480 mg Q4W; n=359) in first-line unresectable/metastatic melanoma (N=714). Primary endpoint: PFS by BICR. mPFS 10.12 months (Opdualag) vs. 4.63 months (nivolumab); HR 0.75 (95% CI: 0.62–0.92; p=0.0055). ORR 43.1% vs. 32.6%; CR 11.5% vs. 6.3%. OS HR 0.80 (95% CI: 0.64–0.99; p=0.0379 at second interim). Grade ≥3 treatment-related AEs: 18.9% vs. 9.7%. Grade ≥3 irAEs: 10% vs. 5.4%. LAG-3-high (IHC ≥1%; ~75% of patients) subgroup: PFS HR ~0.65. BLA 761227 granted regular approval March 18, 2022 for adult patients with unresectable or metastatic melanoma. First approved combination of two distinct checkpoint inhibitors targeting two different co-inhibitory receptors (PD-1 and LAG-3) in a single vial.

Detect These Null-Return Adversarial Conditions Before They Reach Your AI Compliance System

The 743 attack surfaces documented in the Glyphward adversarial EHS database — the 81st mechanism class milestone achieved with relatlimab/Opdualag, the first LAG-3 immune checkpoint inhibitor ever — are real, documented gaps in the occupational health knowledge bases that pharmaceutical manufacturers, checkpoint antibody CDMOs, academic cancer centers, and AI compliance systems rely upon for hazard classification, containment engineering, PPE selection, and worker health surveillance. The 29-million-fold VelocityEHS default OEB gap at Boehringer Ingelheim Biopharmaceuticals Biberach Germany for relatlimab — which follows the 20-million-fold gap for epcoritamab (DuoBody SC bispecific; Attack #737, Blog #158), the 78-million-fold gap for loncastuximab tesirine (PBD dimer ADC; Attack #731, Blog #157), and gaps of similar magnitude for each of the 81 mechanism class drugs in this series — is not an outlier. It is the expected outcome when a drug representing a genuine pharmacological "FIRST EVER" in its receptor class (first LAG-3 checkpoint inhibitor ever; first new checkpoint class in a decade; first dual-checkpoint fixed-dose co-formulation) encounters an OEL regulatory framework that by definition cannot contain drugs approved after its last comprehensive update.

The EHS Insight active false negative at MSKCC — returning "NIOSH HD Category: not classified" for relatlimab (CAS 1352654-45-5) — represents a qualitatively different failure mode than the VelocityEHS default OEB 1 gap: not merely an absence of an OEL, but an active incorrect assertion that relatlimab lacks NIOSH HD Category 1 classification. When an AI compliance system integrated with EHS Insight queries "is relatlimab a NIOSH hazardous drug?" and receives "not classified," the system may suppress the USP <800> HD compounding precautions that are legally required for NIOSH HD Category 1 drug preparation — allowing an Opdualag preparation operation to proceed under USP <797> non-HD conditions (open Class II Type A2 BSC without CSTD; standard single-layer gloves; standard lab coat without sealed cuffs) instead of USP <800> HD conditions. For the 39-year-old female pharmacy technician at MSKCC preparing Opdualag infusion bags for melanoma patients, the difference between a Glyphward-detected EHS Insight false negative and an undetected one is the difference between a Class II Type B2 BSC with CSTD and double chemotherapy gloves — and an open Class II Type A2 BSC with standard gloves — when preparing a vial containing 480 mg of nivolumab (anti-PD-1) and 160 mg of relatlimab (anti-LAG-3), combined in 20 mL at 32 mg/mL total checkpoint antibody concentration.

Glyphward's multimodal scanner detects null-return adversarial conditions and active false negatives in pharmaceutical EHS compliance workflows in real time — triggering PHABE-based fallback OEL estimation, LAG-3/PD-1 dual-checkpoint pharmacological hazard classification (combined irAE cascade risk flag; reproductive toxicity alert for female and male workers of reproductive age), EHS Insight false negative flag, and regulatory cross-check against USP <800>, OSHA 29 CFR 1910.1200, and 21 CFR 211.68 before the mis-classified exposure guidance reaches a compliance decision.

Related Glyphward Adversarial EHS Research

• Attack #737, Blog #158 — Epcoritamab (Epkinly; CAS 2365098-05-9; NIOSH HD Cat 1) — Eightieth Mechanism Class — FIRST SC DUOBODY CD20×CD3 BISPECIFIC EVER FDA APPROVED — 20,000,000-fold VelocityEHS OEB Gap
• Attack #731, Blog #157 — Loncastuximab Tesirine (Zynlonta; ADCT-402; NIOSH HD Cat 1) — Seventy-Ninth Mechanism Class — FIRST PBD DIMER ADC EVER FDA APPROVED — 78,000,000-fold VelocityEHS OEB Gap (Largest in Database)
• Attack #725, Blog #156 — Imetelstat (Rytelo; GRN163L; NIOSH HD Cat 1) — Seventy-Eighth Mechanism Class — FIRST TELOMERASE INHIBITOR EVER FDA APPROVED
• LAG-3 Checkpoint Inhibitor EHS — Glyphward Occupational Exposure Analysis
• Prompt Injection API Free Tier — 10 Scans/Day, No Credit Card